Farrukh T. Awan, MD
Over the past several years, there have been several key developments in the treatment landscape for patients with chronic lymphocytic leukemia (CLL), particularly with the approvals of novel agents such as ibrutinib (Imbruvica) and venetoclax (Venclexta), according to Farrukh Awan, MD.
on Hematologic Malignancies, Awan, an associate professor in the Division of Hematology at The Ohio State University Comprehensive Cancer Center, discussed novel agents and combinations in CLL, as well as the critical importance of FISH and IGHV testing for patient selection in this population.
OncLive: Can you provide an overview of your presentation on CLL?
There has been a lot of excitement in the field of CLL in the last few years. I spoke about patient selection and what kinds of tests we need to do, especially with regards to fluorescence in situ hybridization (FISH) testing and the IGHV
mutational analysis. Those tests are still underutilized, so we want to make sure that there is awareness about them. Those tests should be done on a regular basis in every patient, not just at the time of diagnosis or the time of deciding the initial therapy, but also at the time of subsequent therapies if needed.
... to read the full story